Mass cytometry of acute B cell lymphoblastic leukemias at diagnosis reveals intrapatient phenotypic heterogeneity and specific signatures that mimic cell developmental stage and predict future relapse.
This is a preview of subscription content, log in via an institution to check access.
References
Nowell, P.C. Science 194, 23–28 (1976).
Ferrando, A.A. & López-Otín, C. Nat. Med. 23, 1135–1145 (2017).
Hunger, S.P. & Mullighan, C.G. N. Engl. J. Med. 373, 1541–1552 (2015).
Bhojwani, D. & Pui, C.H. Lancet Oncol. 14, e205–e217 (2013).
Ma, X. et al. Nat. Commun. 6, 6604 (2015).
Good, Z. et al. Nat. Med. 24, 474–483 (2018).
Spitzer, M.H. & Nolan, G.P. Cell 165, 780–791 (2016).
Behbehani, G.K. Clin. Lab. Med. 37, 945–964 (2017).
Somasundaram, R., Prasad, M.A., Ungerbäck, J. & Sigvardsson, M. Blood 126, 144–152 (2015).
Macaulay, I.C., Ponting, C.P. & Voet, T. Trends Genet. 33, 155–168 (2017).
Frei, A.P. et al. Nat. Methods 13, 269–275 (2016).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The author declares no competing financial interests.
Rights and permissions
About this article
Cite this article
Martín-Subero, J. Predicting leukemia relapse. Nat Med 24, 385–387 (2018). https://doi.org/10.1038/nm.4529
Published:
Issue Date:
DOI: https://doi.org/10.1038/nm.4529
- Springer Nature America, Inc.